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ABSTRACT
Human mesenchymal stem cells (MSCs) have increasingly
been used as cellular vectors for the delivery of therapeutic
genes to tumors. However, the precise mechanism of mobili-
zation remains poorly deﬁned. In this study, MSCs that
expressed similar cell surface markers and exhibited multi-
lineage differentiation potentials were isolated from various
donors. Interestingly, different MSC isolates displayed dif-
ferential migration ability toward human glioma cells. We
hypothesized that distinct molecular signals may be
involved in the varied tumor tropisms exhibited by different
MSC isolates. To test this hypothesis, gene expression pro-
ﬁles of tumor-trophic MSCs were compared with those of
non–tumor-trophic MSCs. Among the various differentially
regulated genes, matrix metalloproteinase one (MMP1)
gene expression and its protein activities were enhanced by
27-fold and 21-fold, respectively, in highly migrating MSCs
compared with poorly migrating MSCs. By contrast, there
was no change in the transcriptional levels of other MMPs.
Functional inactivation of MMP1 abrogated the migratory
potential of MSCs toward glioma-conditioned medium.
Conversely, the nonmigratory phenotype of poorly migrat-
ing MSC could be rescued in the presence of either
recombinant MMP1 or conditioned medium from the
highly migrating MSCs. Ectopic expression of MMP1 in
these poorly migrating cells also rendered the cells respon-
sive to the signaling cues from the glioma cells in vivo. How-
ever, blocking the interaction of MMP1 and its cognate
receptor PAR1 effectively diminished the migratory ability
of MSCs. Taken together, this study provides, for the ﬁrst
time, supporting evidence that MMP1 is critically involved
in the migration capacity of MSCs, acting through the
MMP1/PAR1 axis. STEM CELLS 2009;27:1366–1375
Disclosure of potential conﬂicts of interest is found at the end of this article.
INTRODUCTION
Human mesenchymal stem cells (MSCs) are nonhemato-
poietic adult stem cells with multipotent capacities. The
innate tropism of MSCs for tumors, combined with the fact
that these cells can be expanded to a clinical scale production
with ease, have prompted great interest in using MSCs to
deliver antitumor agents to the tumor microenvironment. This
is of particular importance to targeting tumor cells with inva-
sive capacity such as glioma cells. However, the mechanism
and factors responsible for the tumor tropism of MSCs remain
fully elucidated.
MSC migration has been postulated to be similar to hema-
topoietic stem cell (HSC) migration as both cell types reside
in the bone marrow. One of the most widely recognized re-
ceptor/ligand pairs involved in HSC trafﬁcking is the stromal
cell derived factor-1 (SDF-1; also know as chemokine [C-X-C
motif] ligand 12 or CXCL12) and its receptor, chemokine re-
ceptor four (CXCR4), which are crucial for the homing and
engraftment activities of HSC [1–3] as well as for recruitment
of endothelial progenitor cells to sites of ischemic tissues [4].
However, the role of SDF-1/CXCR4 in MSC mobilization is
less clear compare with HSCs. In fact, recent studies have
suggested that SDF-1/CXCR4 axis may not play a major role
in MSC migration. Findings from Ip et al. demonstrated that
the blocking of CXCR4 receptors had no impact on murine
MSC migration [5]. Furthermore, CXCR4/SDF-1 does not
possess the same migration importance in the ability of HSC
to migrate and engraft in immunodeﬁcient animals unless
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ing is recently conﬁrmed in the context of MSCs in which
enforced expression of CXCR4 by lentiviral gene transfer was
demonstrated to enhance homing of MSCs to bone marrow in
vivo [8]. Clearly, a better understanding of the mechanisms
that regulate the migration abilities of MSCs is needed before
these cells could be employed as potent agents for delivering
therapeutic genes to tumor cells.
The signaling cues to mobilize MSCs appear to be depend-
ent on the physiologic/pathologic status of the local environ-
ment. For example, the hepatocyte growth factor/c-met signal-
ing pathway has been implicated in MSC mobilization and
recruitment to damaged tissues [9, 10]. Under hypoxic stress,
MSCs exhibited an increase in the migratory propensity
induced by basic ﬁbroblast growth factor [11] and vascular
endothelial growth factor in the damaged regions [12]. In the
tumor microenvironment, recruitment of MSCs to tumor cells
was associated with elevated expression of proinﬂammatory
molecules such as interleukin-(IL) 6, IL-8, and monocyte che-
moattractant protein-1, which may be mediated by the activa-
tion of urokinase plasminogen activator and its receptors on
human tumor cells [13]. At present, it is unclear whether cyto-
kines, chemokines, growth factors, or proteolytic enzymes acti-
vate the migratory process of MSCs. This is because many of
the studies on MSC migration involved proﬁling the condi-
tioned medium of MSCs that led to the identiﬁcation of many
candidate factors or targeted knockdown of genes which have
been shown to play a role in cellular migration. We have taken
a different approach by performing gene expression proﬁles on
batched MSCs that exhibited high migratory activities versus
those that migrated poorly. This strategy has allowed us to
focus on genes whose products exert a signiﬁcant inﬂuence on
the migration of MSCs toward tumor cells. The candidate gene,
matrix metalloproteinase one or MMP1, was found to be highly
upregulated in highly migratory MSCs that exhibited the tumor
trophic property and was chosen for subsequent studies.
Cellular migration is a complex process that involves the
breakdown of extracellular matrix (ECM) detachment of cells
from the basal membrane, migration of cells from original
location, survival of cells during the migration process, intrav-
asation into target tissue, and ﬁnally, interaction of the
migrated cells with the target microenvironment [14]. The
degradation of ECM during the migration process requires the
action of proteolytic enzymes such as metalloproteinases
(MMPs), which are zinc-dependent endopeptidases [15].
MMPs are secreted as inactive proenzymes or zymogens that
are activated by the cleavage of the prodomain [16]. Depend-
ing on the substrate speciﬁcity and structure, they are divided
into several subgroups: collagenases (e.g., MMP1), stromely-
sins (e.g., MMP3; MMP10), matrilysins (e.g., MMP7;
MMP26), gelatinases (e.g., MMP2; MMP9), and membrane-
type matrix metalloproteinase-1 (MT1-MMP). In particular,
interstitial collagenase (MMP1) has been reported to be
involved in the invasion of breast carcinoma [17]. Stromal-
derived MMP1 was recently shown to cleave and activate the
G-protein-coupled receptor, protease-activated receptor one
(PAR1), leading to activation of intracellular signal that regu-
lates the invasion process in breast cancer cells [18].
In the present study, the functional role of MMP1 in the
migratory activities of various MSC isolates was studied. Tar-
geted knockdown of endogenous MMP1 was shown to inhibit
the migration ability of MSCs in vitro. Conversely, exogenous
expression of MMP1 in poorly migrating MSCs could recon-
stitute the tumor trophic abilities of these cells in vitro and in
vivo. In addition, the disruption of interaction between MMP1
and PAR1 was found to severely impair the migration ability
of MSCs. Taken together, our results showed, for the ﬁrst
time, the functional importance of the MMP1/PAR1 axis in
modulating the migration of MSCs toward human glioma.
MATERIALS AND METHODS
Cell Culture and RNAi Transfection
The Institutional Review Board of National Cancer Center
and Singapore General Hospital have approved this study. Iso-
lation and characterization of MSCs was performed as previ-
ously described [19]. Primary glioma was obtained from a
brain tumor biopsy of a patient diagnosed with grade IV glio-
mas. Normal human astrocytes (NHA), DGli36, and 2-2 cells
were cultured as described previously [19]. Full methods are
available as supporting information.
RNAi transfection was performed using Lipofectamine
RNAiMax (Invitrogen, Carlsbad, CA, http://www.invitrogen.
com). Stealth negative control (medium GC; Invitrogen) was
used as control. In brief, all RNAis were transfected at a ﬁnal
concentration of 20 nM into 1   10
5 cells cultured in a six-
well dish (BD Biosciences, Franklin Lakes, NJ, http://www.
bdbiosciences.com) according to the manufacturer’s protocol.
Construction and Packaging of pHGCX-MMP1
Herpes Simplex Virus-1 Amplicon Viral Vector
The pHGCX-MMP1 Herpes Simplex Virus (HSV)-1 amplicon
plasmid vector which contains the eGFP gene under the con-
trol of the viral immediate early promoter (IE4/5) was
obtained from Dr. Y Saeki (Massachusetts General Hospital,
Boston, MA). The MMP1 gene was inserted into the KpnI and
NotI site located downstream of the strong CMV promoter.
See supporting information Methods for detail information.
In Vitro Migration Assay
A Modiﬁed Boyden chamber assay was used to investigate
the in vitro migration of MSCs. MSCs (1   10
4) were cul-
tured in a 24-well tissue culture insert with an 8 lm pore size
membrane (BD Biosciences). Migration of MSCs across the
membrane was subsequently determined by counting the num-
ber of propidium iodide-stained nuclei on the underside of the
membrane under  200 magniﬁcation. Full method is included
in the supporting information Methods.
In Vivo Migration Assay
MSCs (5   10
4), suspended in 5 ll of complete medium, were
injected into the contralateral hemisphere of DGli36 human
glioma cells-bearing (2   10
5) mice 7 days post-tumor im-
plantation (Bregma [0, 0], 2.0 mm lateral, 2.5 mm depth).
Migration of MSCs from the site of injection was assessed 2
weeks post-MSC cells implantation. Quantiﬁcation of migrated
MSC was performed on single-cell suspension using ﬂow
cytometry. See supporting information Methods for detail. All
animal experiments were performed according to the guide-
lines and protocols approved by the Institutional Animal Care
and Use Committee at the Singapore General Hospital.
Varani Migration Assay
Cell migration was quantiﬁed by recording the number of
cells migrated away from the agarose drops using a method
described by Varani et al. [20]. MSCs were resuspended (1  
10
7 cells per milliliter) in culture medium containing 0.3%
low melting point agarose and maintained at 37 C. Drops of
cell suspensions of approximately 1.5–2 ll were applied to
the center of the wells in a 24-well tissue culture dish. The
dish was then placed on ice for 15 minutes to allow the aga-
rose to solidify. The cell-laden agarose droplets were then
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or fresh culture medium. Cell migration was measured daily for
2 days. Each sample was repeated in triplicate and the experi-
ment was repeated twice. Migrated cells were visualized using
wide-ﬁeld microscopy with an inverted microscope (TE300;
Nikon, Tokyo, Japan, http://www.nikon.com), and images were
acquired on a CCD color digital camera (DXM1200F) using
image acquisition software (ACT-1 v2.7; Nikon).
Affymetrix GeneChip Analysis
The Affymetrix cDNA GeneChip Human Genome U133 Plus
2.0 Array which composed of 47,000 transcripts was used to
identify factors that inﬂuence the migration of MSC. We
compared the gene expression proﬁles of highly migratory
MSCs (MSC-1; MSC-9) and lowly migratory MSCs (MSC-2;
MSC-8). A total of two independent hybridizations were per-
formed using cells of either passage 4 or 5. Five microgram
of total RNA was converted into double-stranded cDNA using
a T7-(dT)24 primer containing T7 RNA polymerase promoter
and Superscript II reverse transcriptase (Affymetrix Inc.,
Santa Clara, CA, http://www.affymetrix.com). cRNA labeling,
hybridizations, washes, and scan steps were performed
according to manufacturer’s instructions (Affymetrix Inc.).
Probe arrays were scanned using the Affymetrix Microarray
Suite, and images were imported as CEL ﬁles into Partek
Genomic Suite (Partek Inc., St. Louis, MO, http://www.partek.
com) for analysis. Genes of interest were matched to those in
the Affymetrix NetAfﬁx Gene Ontology analysis system. The
expression microarray has been submitted to the Gene Expres-
sion Omnibus database at http://www.ncbi.nlm.nih.gov/geo/.
The accession number is GSE12098.
Real-Time Reverse Transcriptase Polymerase Chain
Reaction, MMP1 ELISA, and Bioactivity Assay
Real-time reverse transcriptase polymerase chain reaction (RT-
PCR) was performed as described previously [21]. Quantitation
of pro-MMP1 protein expression and activity were performed
using Quantikine human pro-MMP1 ELISA kit (R&D Systems
Inc., Minneapolis, http://www.rndsystems.com) and MMP1 Bio-
trak activity assay system (GE Healthcare UK Limited, Little
Chalfont, Buckinghamshire, U.K., http://www.gehealthcare.com)
respectively, according to manufacturer’s suggestions. See sup-
porting information Methods for details.
Statistical Analysis
Statistical analyses were performed using Prism 3.0 (Graphpad
Software Inc., San Diego, CA, http://www.graphpad.com).
Nonpaired parametric data were compared with Student’st -test;
for in vivo quantitation of migrated MSCs, paired t-test was
used. p values <.05 were considered statistically signiﬁcant.
RESULTS
Isolation and Tumor-Trophic Characterization of
MSCs In Vitro and In Vivo
Human bone marrow-derived MSCs were isolated as previ-
ously described [19]. Both MSC-1 and MSC-8 were positive
for CD13, CD44, CD90, and CD105, but were negative for
the hematopoietic lineage markers CD34 (hematopoietic stem/
progenitor cells), CD45 (leukocyte), and CD49a (monocytes
and activated T-cells) (supporting information Fig. S1A). In
addition, the abilities of MSCs to differentiate into adipocytes
and osteocytes were demonstrated by the presence of Oil
Red-O staining and von Kossa staining, respectively (support-
ing information Fig. S1B). Primary human glioma biopsy, in
comparison with glioma cells lines, contains a variety of cells
and tissue structures such as ECM, stroma, macrophages, and
tumor cells, which closely resemble the in situ tumor sce-
nario. Using a modiﬁed Boyden chamber assay, MSC-1
exhibited signiﬁcant migration in the presence of either gli-
oma-CM or primary glioma lysates (Fig. 1A). By contrast, the
migratory activities mediated by MSC-8 were greatly impeded
compared with MSC-1, suggesting that the differential migra-
tory potential is an intrinsic property of MSCs. These results
indicate that MSCs are chemoattracted toward soluble factors
secreted by primary human brain tumor and glioma cell line.
Furthermore, different MSC isolates exhibited differential
degrees of tumor tropism in vitro.
To establish if similar behavior was observed in the in vivo
setting, both MSC-1 and MSC-8 were prelabeled with a red ﬂu-
orescent vital dye, CM-DiI, followed by implantation into the
contralateral hemisphere of glioma-bearing mice (Fig. 1B).
Two weeks after injection, with MSCs, these cells had migrated
away from its original injection site and were found in the con-
tralateral hemisphere, speciﬁcally around the peripheral and
within the DGli36 tumor region. CM-DiI-labeled-MSC-1 could
not be detected in the original injection site (i.e., the hemi-
sphere opposite to the implanted DGli36 cells), thus conﬁrming
the tumor trophic property of MSC-1. Furthermore, the percent-
age of CM-DiI-positive MSC-1 in the glioma-bearing hemi-
sphere was 2.83%   0.29% higher than the nonglioma-bearing
hemisphere (Fig. 1B). On the contrary, similarly injected CM-
DiI-labeled-MSC-8 and CM-DiI-labeled NHA were not
detected at the glioma-bearing hemisphere as shown by both
the immunoﬂuorescence image and ﬂow cytometry analysis.
Both MSC-8 and NHA-injected hemisphere exhibited more
CM-DiI positive cells in comparison with the glioma-bearing
region. In fact, the cells remained near or at the injection site.
These results suggested that different MSC isolates exhibited
differential migration ability toward glioma cells.
Differential Migratory Abilities of MSCs Is
Mediated by MMP1
To examine if the observed differential migration ability was
donor-speciﬁc, MSCs harvested from additional eight donors
were tested for their migration activities toward glioma. These
cells were morphologically and immunophenotypically similar
to both MSC-1 and MSC-8. Migration assays were performed
four times using cells restricted to either passage 4 or 5 in an
attempt to minimize variation due to prolonged in vitro cul-
ture. As shown in Figure 2A, differential migration abilities
were observed in the various MSC isolates. Based on the per-
centage of migrated cells, we classiﬁed the MSCs into three
categories, namely, highly migrating (MSC-1 > 66.6%), me-
dium migrating (33.3%   MSC-3, 5, 7, 9, 10   66.6%), and
poorly migrating (MSC-2, 6, 8, 11 < 33.3%).
To identify the molecular pathways involved in the differ-
ential migration activity of MSCs, gene expression proﬁle
between the highly migratory and poorly migratory MSCs
were determined by cDNA microarray using Affymetrix Gen-
eChip Human U133 Plus 2.0 Array. MSCs from the highly
migrating and medium migrating group (MSC-1 and 9) were
compared with those from the poorly migrating group (MSC-
2 and 8). Using Partek software analysis, 239 genes were
found to be upregulated by at least twofold in the highly
migrating/medium migrating MSCs. Many of these genes that
matched to those in the Affymetrix NetAfﬁx Gene Ontology
analysis system belong to chemokines, metalloproteinases,
and cell adhesion molecules, as represented in supporting
information Table S1. Among these candidate genes, MMP1
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fold change (27-fold) with a signiﬁcant p value of .0037. To
determine if the migration activity of MSCs could be corre-
lated to the expression of MMP1, quantitative real-time RT-
PCR analysis was performed (Fig. 2A). The mean expression
values of MMP1 when normalized to 18S were found to be
high (between values of 13 and 100) in highly migrating or
medium migrating groups. On the other hand, MMP1 tran-
scripts were minimally detectable (between values of 0.19
and 4.1) in poorly migrating MSCs. To further conﬁrm the
differential expression of MMP1 in various MSC isolates, the
level of MMP1 protein expression was quantiﬁed using an
ELISA assay. As shown in Figure 2B and 2C, MMP1 expres-
sion (p ¼ .01) and activity was signiﬁcantly higher (p ¼
.004) in the highly migrating MSCs as compared with the
poorly migrating MSCs. Taken together, these results show
that the differential migratory abilities of MSCs are corre-
lated, in part, to the functional expression of MMP1.
MMP2, MMP9, and MT1-MMP have been shown to be
essential for the invasive capacity of human MSCs [22]. As
such, the mRNA expression of these genes was analyzed in
representative cells from each group using real-time RT-PCR
analysis. The levels of MMP2, MMP9, and MT1-MMP tran-
scripts were found to be similar between the highly migrating
(as represented by MSC-1 and MSC-9) and the poorly migrat-
ing cells (as represented by MSC-2 and MSC-8) (Fig. 2D).
This ﬁnding was consistent with our microarray data in that
MMP2, MMP9, and MT1-MMP1 were not differentially
expressed between the two groups of cells. Taken together,
these results indicate that MMP2, MMP9, and MT1-MMP1
are not critical determinants of MSC migration.
Targeted Knockdown of MMP1 RNA Inhibits
Migration and Activity in MSCs
To further conﬁrm the critical role of MMP1 in MSC migration,
RNA interference assays were performed. Three MMP1-RNAi,
namely, MMP1-RNAi-1, MMP1-RNAi-2, and MMP1-RNAi-3,
that target different regions on the MMP1 transcript were syn-
thesized. As shown in supporting information Figure S2A, these
RNAi showed at least 75% reduction in the number of migrated
cells when compared with control-RNAi (ctrl-RNAi)-trans-
fected cells. To ensure an effective MMP1 RNA inhibition,
these RNAi were pooled together and chosen for subsequent
studies (supporting information Fig. S2A). To conﬁrm the tar-
get speciﬁcity of the MMP1-RNAi, the endogenous transcrip-
tional levels of MMP1, MMP2, MMP9, and MT1-MMP in
MSC-1 were determined by real-time PCR. As shown in
Figure 1. Differential migration properties of MSCs. (A): Migration of MSCs toward conditioned medium from glioma cells and primary gli-
oma lysate was analyzed using a modiﬁed Boyden chamber assay. Migration of MSCs was determined by counting the number of propidium
iodide-stained nuclei on the underside of the membrane under  200 magniﬁcations. Bar graph represents number of migrated cells. (B): Coronal
section of the mouse brain indicating the injection site (*) of MSC, and the location of the preimplanted DGli36 human glioma cells (T). Confo-
cal ﬂuorescent images showed the migration of the MSC-1 (upper panel), MSC-8 (middle panel), and normal human astrocytes (lower panel) to
the tumor sites. Images were taken 14 days post-CM-DiI-labeled-MSC injection with a confocal system (LSM 510 Meta; Carl Zeiss, Go ¨ttingen,
Germany) using a  20/0.75 N.A. Plan-Fluor objective. Right panel: ﬂow cytometry analysis of the percentage of CM-DiI cells in the left and
right hemisphere. Purple-ﬁlled curve indicates the percentage of cells in the left hemisphere; green line indicates the percentage of cells in the
right hemisphere. Total number of cells used for ﬂuorescence-activated cell sorting analysis was 1,000,000. Data shown are averages   SEM, n
¼ 4. Abbreviations: DMEM, Dulbecco’s modiﬁed Eagle’s medium; FITC, ﬂuorescein isothiocyanate; MSCs, mesenchymal stem cells.
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at least a 90% knockdown of MMP1 mRNA expression, which
was not observed in ctrl-RNAi-treated-MSC-1 cells. In addi-
tion, in MSC-1 cells treated with either MMP1-RNAi or ctrl-
RNAi, there was no signiﬁcant decrease in the transcriptional
levels of MMP2, MMP9, and MT1-MMP, thus conﬁrming the
speciﬁcity of RNAi against MMP1. The targeted knockdown of
MMP1 gene resulted in corresponding decrease in the level of
MMP1 protein and activity (Fig. 3A). As a consequence, the
number of migrated cells from MMP1-RNAi-MSC-1 was sig-
niﬁcantly reduced when compared with those that were trans-
fected with ctrl-RNAi or naı ¨ve cells. Similar results were
obtained in other highly/medium migrating MSCs, namely,
MSC-3, 5, 7, and 9, which have been transfected with MMP1-
RNAi (supporting information Fig. S2C).
The role of MMP1 in the migration of MSC-1 toward human
glioma was further investigated using Varani migration assay.
MMP1-RNAi-MSC-1 cells showed an inhibited outward dissemi-
nation in the presence of glioma-CM, which was not observed in
ctrl-RNAi-MSC-1 or fresh tissue culture medium (Fig. 3A).
These results provide supporting evidence that the migratory
activities of MSCs are mediated, at least in part, by MMP1.
Impaired Migration of MSCs Can Be Rescued by
Exogenous MMP1 Expression
As MMP1 is a secreted protein, we next ask whether the con-
ditioned medium derived from MSC-1 (MSC-1-CM) could
provide the necessary components to induce migration of the
poorly migrating MSCs (MSC-8 and MSC-2). Our results
showed that MSC-1-CM could effectively rescue the poorly
migratory phenotype of MSC-8 and MSC-2 (Fig. 3B and sup-
porting information Fig. S3A, respectively), with an enhanced
in migratory activities by at least fourfold. Similarly, addition
of exogenous recombinant human MMP1 proteins to MSC-8
and MSC-2 could signiﬁcantly induce the migration of these
cells. By contrast, conditioned medium from MMP1-RNAi-
MSC-1 failed to induce migration of MSC-8 and MSC-2.
In view of the above observations, a gain-of-function
assay was performed to evaluate if overexpression of MMP1
would potentiate the migration of MSC-8 and MSC-2 toward
glioma-CM. We have previously demonstrated that MSCs
could be transduced efﬁciently by a HSV-1 amplicon viral
vector while retaining its stem cell characteristics [19]. To
further conﬁrm the functional involvement of MMP1 in MSC
migration, the gene encoding MMP1 was subcloned into a
HSV-1 amplicon vector (denoted as pHGCX-MMP1) and sub-
sequently packaged into recombinant virions (Fig. 4A). Poorly
migrating MSC, MSC-8, and MSC-2 (shown in supporting in-
formation Figure) were used for the gain-of-function assay.
Poorly migrating MSC-8 was efﬁciently infected by pHGCX-
MMP1. As shown in Figure 4B, using multiplicity of infec-
tion (MOI) of 2.0, approximately 59% of enhanced green ﬂu-
orescent protein (eGFP)þ cells could be detected after 18
hours of infection by FACS analysis. ELISA performed on
Figure 2. MMP1 is differentially expressed in various MSC isolates. (A): Differential migration of MSCs and real-time RT-PCR analysis of
MMP1 transcript in MSCs. Data shown are averages of four replicates of independent experiments. Data shown for real-time RT-PCR are averages
of duplicate samples, experiments were performed independently thrice. (B): Expression of MMP1 in 100 lg of conditioned medium harvested from
various MSCs. Data shown are averages of duplicate wells from representative experiments performed independently thrice. (C): MMP1 activity was
quantitated in conditioned medium harvested from various MSCs. Data shown are averages of duplicate wells   SEM from representative experi-
ments performed independently twice. (D): Real-time RT-PCR analyses of MMP1, MMP2, MMP9, and MT1-MMP transcripts were performed in
highly migratory MSC-1 and MSC-9 versus poorly migrating MSC-2 and MSC-8. For comparison purposes, the fold change of each member of the
MMP was expressed to the human embryonic kidney cells, 293. Data shown are averages of duplicate samples and performed independently twice.
Abbreviations: MMP, matrix metalloproteinase; MSCs, mesenchymal stem cells; MT1, membrane type 1.
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conﬁrmed the ectopic expression of MMP1 in pHGCX-
MMP1-infected cells in comparison with controls (Fig. 4B).
Transwell migration assay subsequently showed a signiﬁcant
increase in the percentage of pHGCX-MMP1-infected-MSC-8
and -2 that had migrated across the ﬁlter membrane, p < .01
(Fig. 4C and supporting information Fig. S3B). By contrast,
MSC transduced with vector alone did not exhibit signiﬁcant
migration compare with naı ¨ve MSC-8. Taken together, these
results conﬁrm the important role of MMP-1 in mediating the
MSC migration.
The effect of MMP1 overexpression on MSC tumor-track-
ing ability was further conﬁrmed in vivo. The highly migrat-
ing MSC-1 was used as positive control and the poorly
migrating naı ¨ve MSC-8 was used as a negative control. Four-
teen days after injecting MSCs into mice bearing intracranial
tumors, the brains were harvested and cryosectioned at 10 lm
thickness. Our results showed that the reconstitution of
MMP1 in MSC-8 could rescue the nonmigratory phenotype of
MSC-8 as indicated by the presence of eGFP positive MSCs
in the tumor region (denoted as T in Fig. 4D). On the con-
trary, pHGCX-transduced-MSC-8 remained close to the injec-
tion site (indicated as ‘‘*’’ in Fig. 4D), exhibiting similar char-
acteristics as the naı ¨ve MSC-8. These results indicated that
MMP1 could sensitize poorly migrating MSCs to signaling
cue from glioma cells. Taken together, we have clearly dem-
onstrated that MSCs with minimal migratory activities can be
reverted by supplementing the cells with recombinant or
exogenous MMP1 gene products, which are essential for the
tumor-trophic migratory activities of MSCs.
Interference of PAR1/MMP1 Axis in Highly
Migratory MSCs Completely Abolish
the Migratory Activities
Recently, the G protein-coupled receptor, PAR1, has been
found to be cleaved by MMP1, which promotes breast cancer
migration and invasion [18]. To investigate whether PAR1
plays a role in MMP1-dependent chemotaxis of MSCs, we
examined whether the inhibition of PAR1 proteolysis may
affect the ability of MSC-1 to migrate toward glioma-CM.
The inhibition of PAR1 activation was performed by incubat-
ing MSC-1 in the presence of an anti-PAR1 monoclonal anti-
body (ATAP2), which speciﬁcally binds to the cleavage
domain of PAR1, thus preventing the proteolysis of PAR1 by
MMP1. Anti-PAR1 treated MSC-1 resulted in an approxi-
mately 85% decrease in the number of MSC-1 migrating to
the glioma-CM in comparison with naı ¨ve MSC-1 (Fig. 5A).
Conversely, no signiﬁcant difference was observed in control
IgG1-treated cells. This observation was further conﬁrmed by
the Varani migration assay in which anti-PAR1-treated MSC-
1 failed to migrate toward glioma-CM (Fig. 5B). Similar
experiments were also performed in poorly migrating MSC-8.
The addition of anti-PAR1 antibodies, but not anti-IgG1, was
Figure 3. Targeted knockdown of MMP1 RNA inhibits migration and activity in MSCs. (A): Migration of MMP1-RNAi-transfected MSC was ana-
lyzed using a modiﬁed Boyden chamber assay. Bar graph represents number of migrated cells. Fluorescent images below showed representative images
of PI-stained cells. Phase contrast photomicrograph showed the migration of MMP1-RNAi-transfected MSCs performed using the Varani migration
assay, as representatively shown as original magniﬁcation  100. All images were visualized using wide-ﬁeld microscopy with an inverted microscope
(TE300; Nikon), and images were acquired on a CCD color digital camera (DXM1200F; Nikon) using image acquisition software, ACT-1 v2.7 (Nikon).
(B): Effect of exogenous MMP1 on the migration proﬁle of poorly migrating MSC-8. Bar graph represents number of migrated cells. In all of the above
experiments, data shown are averages of triplicates   SEM from representative experiment. Abbreviations: CM, conditioned medium; Ctrl, control;
DMEM, Dulbecco’s modiﬁed Eagle’s medium; MMP1, matrix metalloproteinase one; MSCs, mesenchymal stem cells; RNAi, RNA interference.
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oma-CM. The addition of exogenous MMP1 to this anti-
PAR1 treated MSC-8 also did not enhance the migratory
activities (Fig. 5C). This suppressive effect on the migration
of MSC-8 was lifted when exogenous MMP1 was added to
the cells without the presence of PAR1 antibodies, thus dem-
onstrating that MMP1-mediated MSC migration is directed
solely through interaction with its cognate receptor, PAR1.
DISCUSSION
It is becoming increasing clear that achieving targeted traf-
ﬁcking of stem cells will be critical for effective tissue regen-
eration in the clinic. In this study, we have demonstrated that
MSCs exhibit differential tumor tropisms despite the fact that
they were isolated using an identical procedure and cannot be
distinguished based on their phenotypic or multipotential
characteristics. The isolation of MSCs with different tumor-
trophic properties has allowed us to identify the molecular
characteristics of migrating cells in tumor microenvironment.
In particular, the differential migratory activities of MSCs are
mediated, at least partially, by endogenous MMP1 expression.
Cell migration assays were performed to determine the
gliomatrophic properties of our various MSC isolates. Inter-
estingly, we observed that different MSC isolates exhibited
differential migratory activities in vitro, which could be
grouped according to their migratory activities into high, me-
dium, and poor. This is unlikely due to higher cell culture
conﬂuence as reported by De Becker et al. [23], as both
highly migrating and poorly migrating MSCs were seeded
under a mean cellular density that was considered as high
according to the reported experimental conditions.
Figure 4. Overexpression of MMP1 restores the migration of MSC-8. (A): MMP1 gene was inserted into the multiple cloning site located
downstream of the strong CMV promoter on the pHGCX-MMP1 HSV-1 amplicon vector, which contains the eGFP gene. (B): Top: Percentage
of infectivity was determined using FACS for eGFP expression 18 hours postinfection. Flow cytometry FL-1 height analysis demonstrating the
shift in peak of eGFPþ cells at MOI of 2.0. Red line represents mock transduced-MSCs; green-ﬁlled peak represents pHGCX-MMP1-transduced
MSCs. Bottom: MMP1 expression in pHGCX-MMP1-transduced MSC was determined after 48 hours of infection at MOI of 2.0. Data shown are
averages of triplicates   SEM from representative experiment. (C): Migration of pHGCX-MMP1-transduced-MSC-8 was analyzed 48 hours post-
infection using a modiﬁed Boyden chamber assay. Bar graph represents number of migrated cells. Data shown are averages of triplicates  
SEM, experiment was performed independently twice. (D): In vivo migration of pHGCX-MMP1-transduced-MSC-8 in glioma-bearing mice. Con-
focal ﬂuorescent images showed the migration of the CM-DiI-labeled naı ¨ve MSC-1, CM-DiI-labeled naı ¨ve MSC-8, pHGCX-transduced-MSC-8,
and pHGCX-MMP1-transduced-MSC-8 to the tumor sites. Both CM-DiI-labeled naı ¨ve MSC-1 and CM-DiI-labeled naı ¨ve MSC-8 were pseudocol-
ored green. Images were taken 14 days post-CM-DiI-labeled-MSC injection with a confocal system (LSM 510 Meta; Carl Zeiss, Go ¨ttingen, Ger-
many) using a  20/0.75 Numerical Aperture (N.A.) Plan-Fluor objective. Sections were shown at original magniﬁcation  200. *, Injection site,
T, tumor. Abbreviations: amp, ampicillin; bGHpA, bovine growth hormone poly A; CMV, cytomegalovirus; eGFP, enhanced green ﬂuorescent
protein; MFI, mean ﬂuorescence intensity; MMP1, matrix metalloproteinase one; MSCs, mesenchymal stem cells; pac, packaging signal.
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MSCs was clearly demonstrated in intracranial human glioma
xenografts (Fig. 1B). At present, we are uncertain if the differ-
ential migration activities exhibited by the various isolates of
MSCs reﬂected the bona ﬁde pathophysiological state in which
the MSCs are isolated or merely that the pool of MSCs contain
subpopulations at different states of differentiation that are
indistinguishable by cell surface markers. Nevertheless, the
identiﬁcation of these cells has provided us with an approach
to identify distinct signals that are critical to the migration of
MSCs by comparing the two MSC populations in comparative
gene expression studies. By contrast, many of the previous
reports have focused on identifying genes involved with MSC
migratory activities by exposing MSCs to different stimuli or
tumor CM before gene proﬁle expression assays [24, 25].
Using DNA microarray analysis, our results showed that
MMP1 is signiﬁcantly upregulated ( 27-fold) in highly
migrating MSCs in comparison with the poorly migrating
MSCs. This was conﬁrmed by the  10-fold to 1,000-fold
higher level of MMP1 transcripts in the highly migratory
MSCs compare with poorly migratory MSCs using real-time
PCR. The differential mRNA expression of MMP1 was further
supported by ELISA assay: MSCs with greater migratory activ-
ities were shown to secrete substantial amounts of MMP1 pro-
teins into the culture supernatants (Fig. 2B). In addition, the
level of active MMP1 was found to be tightly correlated with
the migratory activities of various MSC isolates (Fig. 2C).
Ideally, the relative amount of MMP1 RNA transcripts, MMP1
protein expression and functional cell migratory activities
should be consistent among the various MSC isolates. For
example, the top three MSC isolates with the highest migratory
activities were MSC-1 (100   16.22), MSC-7 (60.88   1.65),
and MSC-3 (56.63   9.39). The MMP1 RNA levels were also
found to be in the same order (Fig. 2A). However, the level of
MMP1 protein expression was found to be highest from MSC-
1, followed by that found in MSC-9 and MSC-3 (Fig. 2B).
These interexperimental variations could be explained as each
of the assays (RNA, protein, or cell migration) was performed
at different times even though special care was taken to ensure
that all experiments were performed using cells of passage 4 to
5. Nevertheless, the overall MMP1 mRNA, protein, and migra-
tion proﬁles were consistent among the highly migrating versus
the poorly migrating MSCs.
MMPs are generally known for their roles in tissue
remodeling by degradation of ECM and basement membrane
components. However, MMPs have also been implicated in
the activation of growth factors and cytokines by degrading
their precursors or inhibitors, thereby adjusting the cancer
cells to the tissue microenvironment [26, 27]. MMP1 has
been shown to degrade insulin-like growth factor binding pro-
teins (IGFBP)-3 and -5 [28, 29]. This in turn modulates the
bioavailability of the insulin-like growth factors (IGFs)
depending on tissue types and physiologic/pathologic status
[30]. For example, MMP9 induced IGFBP2-IGF2 complex
proteolysis resulted in the extracellular release of free IGF2
with positive and biologic effect on astrocytoma cellular
growth and migration [30]. From our microarray results, the
level of IGF2 transcripts was the second highest in MSCs
with greater mobility in comparison with those that migrate
poorly (supporting information Table S1). Thus, it is possible
that MMP1 could also act as an IGFBP2 proteinase; the
observed elevated level of IGF2 could represent the released,
unbound IGF2 that ultimately initiates the mobilization of
MSCs. Alternatively, the migration process may also be
guided by cytokines, such as IL-8, and chemokines, such as
CXCL1 and CXCL2, all of which have been found to be ele-
vated in the highly migratory MSC population. The precise
Figure 5. Functional MMP1/PAR1 axis mediates MSC migration.
(A): Effect of anti-PAR1 blocking antibody on the migration of
MSC-1 was examined using a modiﬁed Boyden chamber assay. Bar
graph represents number of migrated cells. Data shown are averages
of triplicates   SEM, experiment was repeated independently three
times. Photomicrograph showed the representative images of PIþ
migrated cells at original magniﬁcation  200. (B): Varani migration
assay was performed to conﬁrm the effect of PAR1 on MSC migra-
tion. Photomicrograph showed migration of MMP1-RNAi-transfected
MSCs. Representative images from two independent experiments
were shown. Images were shown as original magniﬁcation x100.
Slides were visualized using wide-ﬁeld microscopy with an inverted
microscope (TE300; Nikon), and images were acquired on a CCD
color digital camera (DXM1200F; Nikon) using image acquisition
software, ACT-1 v2.7 (Nikon). (C): Effect of MMP1/PAR1 interac-
tion on the migration ability of MSC-8 treated with the various pro-
teins was examined using a modiﬁed Boyden chamber assay. Bar
graph represents number of migrated cells. Data shown are averages
of triplicates   SEM, experiment was performed independently twice.
Abbreviations: CM, conditioned medium; MSCs, mesenchymal stem
cells; PAR1, protease-activated receptor one.
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MSCs will require further study.
Interestingly, even though platelet derived growth factor b
(also known as PDGF-BB), MMP2, MMP9, and MT1-MMP
were reported to be players mediating the migration and inva-
sion of MSCs in vitro [22, 31], upregulation of these genes in
highly migratory MSCs was not observed. Similarly, there
was no signiﬁcant difference in the level of MMP2, MMP9,
and MT1-MMP transcripts expression between the highly mi-
gratory (MSC-1 and MSC-9) versus poorly migratory MSCs
(MSC-2 and MSC-8) when analyzed using real-time RT-PCR
(Fig. 2). However, the design of this experimental study does
not take into account the possible synergistic effect of these
MMPs in the regulation of MSC mobilization. Hence, we
could not exclude that these MMPs may still play a role in
the overall mobilization of MSCs.
Recently, Boire et al. reported that PAR1 is a MMP1 re-
ceptor that promote invasion and tumorigenesis of breast can-
cer cells in vitro and in vivo [18]. Shi et al. showed that
blocking PAR1 cleavage and activation using anti-PAR1 anti-
body could inhibit invasion and chemotaxis of prostate cancer
cells [32]. Using a monoclonal antibody against PAR1, we
showed that blocking the MMP1/PAR1 interaction signiﬁ-
cantly reduced the migration ability of MSCs. The importance
of this axis in MSC migration was further supported by the
lack of migratory response when recombinant MMP1 was
added to cells previously incubated in anti-PAR1 antibody.
Furthermore, Western blot analysis showed that the PAR1
expression level was similar in highly migrating versus poorly
migrating MSCs (supporting information Fig. S4). Thus, it
appears that the level of MMP1 expression and the speciﬁc
interaction of MMP1 with PAR1 proteins determine the dif-
ferential migration ability of MSCs. In bone marrow-derived
MSCs, the level of MMP1 was reported to be regulated by
the hypoxia-inducible factor-1a [33]. Ectopic expression of
the secretory form of ﬁbroblast growth factor-1 could also
induce MMP1 transcription in endothelial cells, thus resulting
in enhanced migratory activities [34]. On the other hand,
PAR1 activation in human late endothelial progenitor cells
has been shown to enhance the mRNA levels of both SDF-1
and CXCR4 [35]. We have not studied the SDF-1/CXCR4
axis closely because these genes were not differentially
expressed between the highly migrating and poorly migrating
MSCs. This ﬁnding might explain the observation why only a
small subpopulation of human MSC has been shown to
express functional CXCR4 receptors [36]. However, we could
not exclude these genes from providing secondary support
that may assist in the mobilization of MSCs. At present, the
potential role of MMP1 in regulating SDF-1 expression is
unknown; it is also unclear whether MMP1/PAR1 axis acts
directly or indirectly on SDF-1 and/or CXCR4 activation. As
such, further research is necessary to dissect the relation
between the two pathways. Nevertheless, it is becoming clear
that both the ECM and the microenvironment surrounding
MSCs are not merely scaffold, but also harbor cryptic biologi-
cal functions that may regulate the migration, plasticity, self-
renewal and pluripotency of MSCs.
In conclusion, we report that the migratory activity of
MSCs toward glioma is mediated via the MMP1/PAR1 axis
in vitro and in vivo. An adequate understanding of the tumor
tropism of MSC bears important implication for effective cel-
lular delivery of therapeutic agents for brain tumor therapy.
CONCLUSION
Our results highlighted the critical role that MMP1 plays in
the process of mobilizing MSCs toward human glioma cells.
MSCs expressing low levels of MMP1 fail to response to sig-
naling cues from human glioma cells even though other
MMPs are present at levels similar to the highly migrating
MSCs. Targeted knockdown of MMP1 or the inactivation of
PAR1 that disrupt its association with MMP1 resulted in the
lost of MSC migratory activities. Anti-PAR1 antibodies
treated MSCs could not migrate even in the presence of exog-
enous MMP1, suggesting that both MMP1 levels and the spe-
ciﬁc interaction between MMP1 and PAR1 are important fac-
tors that determine the migratory abilities of MSCs. To our
knowledge, this is the ﬁrst comprehensive report on the
involvement of MMP1 on the migration of MSCs via the acti-
vation of the PAR1 receptor.
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